GlassScriptPhysician profile
Mark David Stavitsky
NPI 1902999709
$1,247.96
in general payments reported to CMS, 2019-2025
15 companies · $119 in 2025
The $119 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $83.26 · 2021: $265 · 2022: $261 · 2023: $179 · 2024: $123 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $450.17 | 2020-2023 | Dyanavel Xr |
| Corium, LLC | $203.29 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $141.69 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $132.54 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $52.05 | 2022-2023 | Gardasil 9, Rotateq, Vaxneuvance |
| Genentech USA, INC. | $39.16 | 2019 | |
| Sanofi Pasteur INC. | $38.52 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $36.97 | 2025 | Jornay Pm |
| Seqirus USA INC | $30.74 | 2024 | Flucelvax |
| Kaleo, INC. | $28.48 | 2020-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $22.01 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $20.76 | 2025 | Neffy |
| Cranial Technologies, INC | $20.54 | 2025 | Doc Band |
| Adlon Therapeutics L.P. | $16.05 | 2020 | |
| Aytu Biopharma, INC. | $14.99 | 2024 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stavitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.